Menu Search
Equities

Perspective Therapeutics Inc

AAJ:FRA

Perspective Therapeutics Inc

Actions
  • Price (EUR)1.39
  • Today's Change0.06 / 4.51%
  • Shares traded-1.00
  • 1 Year change+227.83%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 07:02 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Perspective Therapeutics, Inc. is a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents. The Company is focused on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies, so its targeted medical doses are delivered directly to the tumor site. The Company’s core product is its Cesium-131 sealed source brachytherapy seed. These seeds can be inserted individually or in combination into various locations in the body. The Company also sells seeds in strands to keep them from individually moving. The Company’s segments are Brachytherapy and Drug Operations. Brachytherapy includes sales and manufacturing of Cesium-131 brachytherapy seeds, including research and development of new applications for the seeds. Drug Operations includes research and development and clinical operations related to the use of Lead-203 and Lead-212 as a diagnostic and a therapeutic drug.

  • Revenue in USD (TTM)-304.00k
  • Net income in USD-48.91m
  • Incorporated2018
  • Employees116.00
  • Location
    Perspective Therapeutics Inc2401 Elliott Avenue, Suite 320SEATTLE 98121United StatesUSA
  • Phone+1 (509) 375-1202
  • Fax+1 (302) 636-5454
  • Websitehttps://isoray.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.